Associate Professor, Internal Medicine, Rush University Medical Center
Hematology
Dr. Jamile M. Shammo, MD
|
|
Give Review
Jamile Shammo works in the field of Hematology. She received awards:"CMS Meaningful Use Stage 1 Certification". Jamile Shammo has written publications. She has 17 publications published with PubMed. The lastest paper is: 'Extended survival and reduced risk of AML progression in erythroid responsive lenalidomide-treated patients with lower-risk del(5q) MDS.' Jamile Shammo accepts Medicare.
Publications
- Extended survival and reduced risk of AML progression in erythroid responsive lenalidomide-treated patients with lower-risk del(5q) MDS.
- Randomized, dose-escalation study of the p38? MAPK inhibitor SCIO-469 in patients with myelodysplastic Syndrome.
- Age-related differences in Disease characteristics and clinical outcomes in polycythemia vera.
- Sideroblastic Anemia due to linezolid in a patient with a left ventricular assist device.
- Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic Syndrome and thrombocytopenia.
- Idiopathic hemophagocytic Syndrome with a fulminant clinical course.
- Clinical roundtable monograph. MDS classification and risk stratification.
- Granulocyte-macrophage colony stimulating factor-induced Immune priming of cyclophosphamide, doxorubicin, vincristine, and prednisone with rituximab chemoimmunotherapy...
- Safety and efficacy of combination therapy with fludarabine, mitoxantrone, and rituximab followed by yttrium-90 ibritumomab tiuxetan and maintenance rituximab as front...
- Successful treatment of amegakaryocytic thrombocytopenia with eltrombopag in a patient with systemic lupus erythematosus (SLE).
- An examination of educational gaps in the diagnosis and treatment of myelodysplastic Syndromes.
- Use of a tumor-cell enrichment column for the enhanced detection of minimal residual Disease in the BM or apheresis peripheral blood transplant products of breast-canc...
- Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative Disease: outcomes and prognostic factors in the modern ...
- Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic Syndromes with karyotypes other than deletion 5q.
- The combination of fludarabine, cyclophosphamide, and granulocyte-macrophage colony-stimulating factor in the treatment of patients with relapsed Chronic lymphocytic l...
- First two cases of immune hemolytic Anemia associated with ceftizoxime.
Procedures Preformed
- Plasmapheresis
Conditions Treated
- Acute Leukemia
- Anemia
- Antiphospholipid Syndrome (APS)
- Chronic Myeloid Leukemia (CML)
- View All
Doctors Specialties
- Hematology
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
Education
-
University of Chicago -
McGaw Medical Center of Northwestern University -
University of Aleppo Faculty of Medicine
Hospital
-
Rush University Medical Center
Drug Facts
| NPI NUMBER | 1316906779 | |
| NPPES Provider LastName | SHAMMO | |
| NPPES Provider FirstName | JAMILE | |
| NPPES Provider ZIPCode | 606123841 | |
| NPPES Provider State | IL | |
| Specialty Description | Hematology | |
| Total Claim Count | 146.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1316906779 |
| Last Name Of The Provider | SHAMMO |
| First Name Of The Provider | JAMILE |
| View All |
Similar Doctors
|
|
Dr. Shira N. Dinner, MD |
|
|
Dr. Manjeet S. Chawla, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Alan D. Gilman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mohammed A. Kassem, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Ashok R. Patel, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mark J. Roberts, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Emily K. Curran, MD |
|
|
Dr. Steven B. Maron, MD |
|
|
Dr. Seerin V. Shatavi, MD |